Monte Carlo-Based Nanoscale Dosimetry Holds Promise for Radiopharmaceutical Therapy Involving Auger Electron Emitters.
Ohyun KwonSabrina L V HoffmanPaul A EllisonBryan P BednarzPublished in: Cancers (2024)
Radiopharmaceutical therapy (RPT) is evolving as a promising strategy for treating cancer. As interest grows in short-range particles, like Auger electrons, understanding the dose-response relationship at the deoxyribonucleic acid (DNA) level has become essential. In this study, we used the Geant4-DNA toolkit to evaluate DNA damage caused by the Auger-electron-emitting isotope I-125. We compared the energy deposition and single strand break (SSB) yield at each base pair location in a short B-form DNA (B-DNA) geometry with existing simulation and experimental data, considering both physical direct and chemical indirect hits. Additionally, we evaluated dosimetric differences between our high-resolution B-DNA target and a previously published simple B-DNA geometry. Overall, our benchmarking results for SSB yield from I-125 decay exhibited good agreement with both simulation and experimental data. Using this simulation, we then evaluated the SSB and double strand break (DSB) yields caused by a theranostic Br-77-labeled poly ADP ribose polymerase (PARP) inhibitor radiopharmaceutical. The results indicated a predominant contribution of chemical indirect hits over physical direct hits in generating SSB and DSB. This study lays the foundation for future investigations into the nano-dosimetric properties of RPT.
Keyphrases
- circulating tumor
- cell free
- monte carlo
- single molecule
- dna damage
- high resolution
- radiation therapy
- physical activity
- mental health
- electronic health record
- circulating tumor cells
- dna repair
- systematic review
- computed tomography
- photodynamic therapy
- virtual reality
- quantum dots
- young adults
- replacement therapy
- positron emission tomography
- liquid chromatography
- cell therapy
- light emitting
- chemotherapy induced